SCHEMBL6318635

SCHEMBL6318635

COc1ccc(C2C(CC(=O)O)C2(Br)Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.46
ITGAV P06756 1/20 0.46
ITGB5 P18084 1/20 0.46
ITGB6 P18564 1/20 0.46
EDNRA P25101 2/20 0.40
EDNRB P24530 1/20 0.40
MIF P14174 1/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
GSK3B P49841 1/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325205 0.83 ITGB3 (0.47) ITGB3ITGAVITGB5ITGB6EDNRA
SCHEMBL6324398 0.83 ITGB3 (0.47) ITGB3ITGAVITGB5ITGB6EDNRA
SCHEMBL6324394 0.83 ITGB3 (0.47) ITGB3ITGAVITGB5ITGB6EDNRA
SCHEMBL6320804 0.82 MAPT (0.48) ITGB3ITGAVITGB6EDNRAEDNRB
SCHEMBL6319125 0.78 CA12 (0.35) LMNAGAAKDM4EALDH1A1HPGD
SCHEMBL2435013 0.69 HTR2C (0.59) ITGB3ITGAVITGB5ITGB6EDNRA
SCHEMBL6317160 0.68 EDNRA (0.47) EDNRAEDNRBLMNAGAAKDM4E
SCHEMBL6317175 0.68 EDNRA (0.47) EDNRAEDNRBLMNAGAAKDM4E
SCHEMBL6317044 0.68 EDNRA (0.47) EDNRAEDNRBLMNAGAAKDM4E
SCHEMBL20838730 0.68 DGAT1 (0.60) KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501830-A1 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES Actelion Pharmaceuticals Ltd. (CH) 2005-02-02 EP claimed
WO-2003093267-A1 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS LTD (CH) 2003-11-13 WO claimed
US-6921767-B2 Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION (US) 2005-07-26 US disclosed
US-20040092538-A1 Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092538-A1 Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives ITGA5, ITGB5, ITGB3 ITGB3 3/4885ITGAV 6/4885ITGB5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.